TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ascentage Pharma Group International Unsponsored ADR ( (AAPG) ) has issued an announcement.
On December 1, 2025, Ascentage Pharma announced it will host an investor webcast on December 11, 2025, to highlight key data from the 67th American Society of Hematology Annual Meeting. This event will provide updates on the company’s innovative portfolio and pipeline, featuring presentations by the management team. The webcast aims to reinforce Ascentage Pharma’s position in the biopharmaceutical industry by showcasing its ongoing research and development efforts, potentially impacting stakeholders by enhancing the company’s visibility and credibility in the market.
The most recent analyst rating on (AAPG) stock is a Sell with a $33.00 price target. To see the full list of analyst forecasts on Ascentage Pharma Group International Unsponsored ADR stock, see the AAPG Stock Forecast page.
Spark’s Take on AAPG Stock
According to Spark, TipRanks’ AI Analyst, AAPG is a Underperform.
The overall stock score reflects significant financial challenges, including high debt levels and negative profitability, which are the most impactful factors. The technical analysis indicates weak momentum, and the valuation is unattractive due to negative earnings and lack of dividends. These factors collectively result in a low overall score.
To see Spark’s full report on AAPG stock, click here.
More about Ascentage Pharma Group International Unsponsored ADR
Ascentage Pharma Group International is a global, commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapies to address unmet medical needs in cancer. The company has developed a robust pipeline of innovative drug products, including inhibitors targeting key apoptotic pathway proteins and next-generation kinase inhibitors. Ascentage Pharma’s notable products include Olverembatinib, a third-generation BCR-ABL1 inhibitor approved in China for specific types of chronic myeloid leukemia, and Lisaftoclax, a Bcl-2 inhibitor for treating hematologic malignancies.
Average Trading Volume: 8,037
Technical Sentiment Signal: Hold
Current Market Cap: $3.05B
Learn more about AAPG stock on TipRanks’ Stock Analysis page.